Drug intelligence / Profile preview

AdVhAFP

Development stage
Phase 1
Lead developer
University of Pittsburgh
Modality
Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration
Intradermal, Subcutaneous, Ex Vivo
01

Overview

AdVhAFP is a recombinant, replication-deficient adenoviral vector engineered to express the human alpha-fetoprotein (AFP) gene. It is designed as an immunotherapy for hepatocellular carcinoma (HCC), a malignancy that frequently overexpresses AFP as a tumor-associated antigen. The vector is primarily used to transduce dendritic cells (DCs) ex vivo or administered directly to induce and expand AFP-specific CD4+ helper and CD8+ cytotoxic T-cell responses. By utilizing an adenoviral delivery system, the therapy aims to overcome immunological tolerance to AFP, which is a self-antigen, thereby promoting a robust Th1-skewed immune response capable of recognizing and eliminating AFP-positive tumor cells.

Other names
AFP-expressing adenovirusAdenovirus-hAFPhAFP-adenovirus
02

Targets

AFP (Alpha-fetoprotein)

Beyond the preview

Go deeper on AdVhAFP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdVhAFP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call